UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

Annals of oncology, 2011-06, Vol.22 (6), p.1382-1391

2011

Volltextzugriff (PDF)

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Journal of cellular and molecular medicine, 2023-07, Vol.27 (14), p.1928-1946

2023

Volltextzugriff (PDF)

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

British journal of haematology, 2008-11, Vol.143 (3), p.395-403

2008

Volltextzugriff (PDF)

A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma

European journal of haematology, 2001-01, Vol.66 (1), p.24-30

2001

Volltextzugriff (PDF)

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Cancer, 2010-11, Vol.116 (21), p.5001-5011

2010

Volltextzugriff (PDF)

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

European journal of haematology, 2008-03, Vol.80 (3), p.227-235

2008

Volltextzugriff (PDF)

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy

Haematologica (Roma), 2011-07, Vol.96 (7), p.996-1001

2011

Volltextzugriff (PDF)

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse

Haematologica (Roma), 2011-07, Vol.96 (7), p.1002-1007

2011

Volltextzugriff (PDF)

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Journal of medical case reports, 2020-09, Vol.14 (1), p.138-138, Article 138

2020

Volltextzugriff (PDF)

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma

Cancer, 2002-08, Vol.95 (3), p.576-580

2002

Volltextzugriff (PDF)

Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non‐Hodgkin lymphoma

British journal of haematology, 2010-03, Vol.148 (5), p.808-810

2010

Volltextzugriff (PDF)

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

European journal of haematology, 2007-02, Vol.78 (2), p.93-101

2007

Volltextzugriff (PDF)

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

Hematological oncology, 2011-03, Vol.29 (1), p.10-16

2011

Volltextzugriff (PDF)

combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma

Annals of hematology, 2009-05, Vol.88 (5), p.425-432

2009

Volltextzugriff (PDF)

The role of hematopoietic SCT in adult Burkitt lymphoma

Bone marrow transplantation (Basingstoke), 2013-05, Vol.48 (5), p.617-629

2013

Volltextzugriff (PDF)

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas

Haematologica (Roma), 2003-08, Vol.88 (8), p.888

2003

Volltextzugriff (PDF)

Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma

Cancer, 2002-02, Vol.94 (4), p.873-878

2002

Volltextzugriff (PDF)

A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy

European journal of haematology, 2002-06, Vol.68 (6), p.354-361

2002

Volltextzugriff (PDF)

Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

Leukemia & lymphoma, 2006-04, Vol.47 (4), p.603-611

2006

Volltextzugriff (PDF)

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial

European journal of haematology, 1996-11, Vol.57 (5), p.377-383

1996

Volltextzugriff (PDF)

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

Haematologica (Roma), 2016-10, Vol.101 (10), p.e407-e410

2016

Volltextzugriff (PDF)

The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non‐Hodgkin's B‐Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

The oncologist (Dayton, Ohio), 2013-05, Vol.18 (5), p.625-633

2013

Volltextzugriff (PDF)

Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas

The American journal of surgical pathology, 2012-02, Vol.36 (2), p.296-304

2012

Volltextzugriff (PDF)

Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna Experience

Leukemia & lymphoma, 1999-01, Vol.32 (5-6), p.571-576

1999

Volltextzugriff (PDF)

Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma

Gan to kagaku ryoho, 2015-01, Vol.42 (1), p.51

2015

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(123)

Sprache

Englisch
(121)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(123)
Science & Technology
(115)
Life Sciences & Biomedicine
(114)
Middle Aged
(114)
Male
(113)
Female
(111)
Aged
(83)
Oncology
(75)
Hematology
(65)
Lymphoma, Non-Hodgkin - Drug Therapy
(65)
Adolescent
(64)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(62)
Biological And Medical Sciences
(58)
Medical Sciences
(58)
Treatment Outcome
(51)
Cyclophosphamide - Administration & Dosage
(42)
Lymphoma, Non-Hodgkin - Mortality
(41)
Prognosis
(38)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(37)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma

Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non‐Hodgkin lymphoma

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma

The role of hematopoietic SCT in adult Burkitt lymphoma

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas

Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma

A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy

Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non‐Hodgkin's B‐Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas

Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna Experience

Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma

Aktive Filter

Suchergebnisse filtern